1VA Puget Sound Health Care System, Seattle, Washington 2Harborview Medical Center, University of Washington, Seattle, Washington 3Orthopedic + Fracture Specialists, Portland, Oregon 4Orthopaedic Associates of Michigan, Grand Rapids, Michigan 5Twin Cities Orthopedics, Edina, Minnesota 6Orthopaedic & Spine Center of the Rockies, Fort Collins, Colorado.
J Bone Joint Surg Am. 2017 Nov 1;99(21):1792-1800. doi: 10.2106/JBJS.16.01471.
We analyzed self-reported outcomes in a prospective cohort of patients treated with ankle arthrodesis or total ankle replacement (TAR) during a time of transition from older to newer-generation TAR implants.
We performed a prospective cohort study comparing outcomes in 273 consecutive patients treated for ankle arthritis with arthrodesis or TAR between 2005 and 2011. Adult patients with end-stage ankle arthritis who were able to walk and willing and able to respond to surveys were included in the study. Patients were excluded when they had another lower-limb problem that might affect walking. At baseline and at 6, 12, 24, and 36-month follow-up visits, participants completed a pain score, a Musculoskeletal Function Assessment (MFA), and a Short Form-36 (SF-36) survey.
There was significant mean improvement in most outcomes after surgery regardless of procedure. In general, the greatest improvement occurred during the first 6 months of follow-up. Linear mixed-effects regression adjusted for differences at baseline in age, body mass index (BMI), and surgery type showed that at 6 months the scores were improved by a mean (and standard error) of 12.6 ± 0.7 (33%) on the MFA, 22.0 ± 1.4 (56%) on the SF-36 Physical Functioning (PF) scale, 32.4 ± 1.6 (93%) on the SF-36 Bodily Pain (BP) scale, and 4.0 ± 0.2 (63%) on the pain rating scale. The mean improvements in the MFA and SF-36 PF scores over the 3-year follow-up period were significantly better after the TARs than after the arthrodeses, with differences between the 2 groups of 3.6 ± 1.6 (p = 0.023) and 7.5 ± 2.9 (p = 0.0098), respectively. The differences between the 2 groups were slightly greater when only the newer TAR devices were compared with the arthrodeses (MFA = 3.8 ± 1.8 [p = 0.031], SF-36 PF = 8.8 ± 3.3 [p = 0.0074], SF-36 BP = 7.3 ± 3.6 [p = 0.045], and pain score = 0.8 ± 0.4 [p = 0.038]).
Patients reported improved comfort and function after both surgical treatments. The average improvement in the MFA and SF-36 PF scores was better after TAR than after arthrodesis, particularly when the TAR had been done with later-generation implants. Younger patients had greater functional improvements than older patients.
Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
我们分析了前瞻性队列中接受踝关节融合或全踝关节置换术(TAR)治疗的患者的自我报告结果,这些患者在从旧一代 TAR 植入物向新一代 TAR 植入物过渡期间接受了治疗。
我们进行了一项前瞻性队列研究,比较了 2005 年至 2011 年间接受踝关节关节炎融合或 TAR 治疗的 273 例连续患者的结果。纳入研究的患者为终末期踝关节关节炎,能够行走且愿意并能够回答调查问题。当患者存在可能影响行走的另一下肢问题时,则将其排除在外。在基线以及 6、12、24 和 36 个月的随访期间,参与者完成了疼痛评分、肌肉骨骼功能评估(MFA)和简明健康状况调查问卷 36 项(SF-36)调查。
无论手术类型如何,手术后大多数结果均有显著的平均改善。一般来说,最大的改善发生在随访的前 6 个月。线性混合效应回归调整了基线时年龄、体重指数(BMI)和手术类型的差异,结果显示,在 6 个月时,MFA 评分平均(标准差)改善 12.6±0.7(33%),SF-36 生理功能(PF)量表改善 22.0±1.4(56%),SF-36 身体疼痛(BP)量表改善 32.4±1.6(93%),疼痛评分改善 4.0±0.2(63%)。在 3 年的随访期间,TAR 后 MFA 和 SF-36 PF 评分的平均改善明显优于融合术后,2 组之间的差异分别为 3.6±1.6(p=0.023)和 7.5±2.9(p=0.0098)。当仅将较新的 TAR 设备与融合术进行比较时,2 组之间的差异稍大(MFA=3.8±1.8[p=0.031],SF-36 PF=8.8±3.3[p=0.0074],SF-36 BP=7.3±3.6[p=0.045],疼痛评分=0.8±0.4[p=0.038])。
患者报告在接受两种手术治疗后舒适度和功能均得到改善。TAR 后的 MFA 和 SF-36 PF 评分平均改善优于融合术,尤其是在使用较新一代植入物进行 TAR 时。年轻患者的功能改善比老年患者更大。
治疗性 II 级。请参阅作者说明,以获取完整的证据水平描述。